Nektar Therapeutics Company

Nektar Therapeutics develops therapeutics based on its advanced polymer conjugate chemistry technology platform.
Technology:
Biotechnology, CAR-T therapy, Cell therapy, Chemical, Health Care, Therapeutics
Industry:
Pharma, Public
Headquarters:
San Carlos, California, United States
Founded Date:
1990-01-01
Employees Number:
501-1000
Funding Status:
IPO
Acquisitions Number:
2
Investors Number:
4
Total Funding:
1169999960
Estimated Revenue:
$50M to $100M
Last Funding Date:
2021-02-17
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership